Rituximab for Scleroderma: Does Something Finally Work? PDF Print E-mail
Tuesday, 06 April 2010 20:37
Kevin Deane, MD
Posted: 03/10/2010

Experience With Rituximab in Scleroderma: Results From a 1-Year, Proof-of-Principle Study
Daoussis D, Liossis SN, Tsamandas AC, et al. Rheumatology (Oxford). 2010;49:271-280

Background
Multiple drugs have been tried in scleroderma to improve both skin disease and pulmonary disease. However, most of these studies have failed to show significant benefit. In an open-label study, Daoussis and colleagues investigated the effect of the B-cell directed agent rituximab in improving pulmonary function and skin disease in scleroderma.

Study Summary
Eight patients with scleroderma were given rituximab for 2 cycles 24 weeks apart; each cycle consisted of 375 mg/m2 weekly, for a total of 4 doses. Lung and skin measures at baseline and 1 year after treatment were compared within the group of treated patients and with results in 6 patients with scleroderma treated with other agents, including mycophenolate, corticosteroids, cyclophosphamide, and bosentan (patients receiving rituximab may have also given these agents). All patients had diffuse scleroderma, were Scl-70 positive, and had clinically significant interstitial lung disease.

The rituximab-treated patients had improvement in forced vital capacity and diffusing carbon monoxide compared with their baseline values and compared with controls. Functional status also improved in 6 rituximab-treated patients, with a decrease in Health Assessment Questionnaire score of 0.2. Finally, skin thickening improved in rituximab-treated patients compared with their baseline status, and in several patients, skin fibrosis on skin biopsy was reduced. No mortality benefit was reported. The authors conclude that rituximab may improve lung function and skin scores in patients with scleroderma, and they propose larger randomized studies to investigate further the role of rituximab in treatment of scleroderma.

Viewpoint
The failure of multiple treatments to show clinically meaningful and statistically significant improvement in scleroderma has been frustrating for those who treat this devastating disease. Evidence that B cells may be important in the pathogenesis of scleroderma[1] has served as the rationale for Daoussis and colleagues’ study, and their results are promising. However, the sample was small, and we need to be cautious in terms of how much excitement the findings generate. As the authors rightly point out, their study should serve to stimulate large, randomized placebo-controlled trials for scleroderma and stimulate further investigation into the role of B cells in the pathogenesis of this disease. Of importance will be which outcomes are assessed in future studies. Improvements in measures of lung physiology are important, but ultimately quality of life and mortality need to improve.

References
1. Lafyatis R, O'Hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum. 2007;56:3167-3168.
 
More articles :

» Two Problems That People With Scleroderma Face: Malabsorption and Inflammation

According to , many doctors agree that starts with inflammation, and its progress depends on how much inflammation continues to occur in the body. That's one reason some doctors recommend that patients with any sort of inflammatory disease such as...

» Scientists Identify Agent That Can Block Fibrosis of the Skin and Lungs

Researchers at the have identified an agent that in lab tests protected the skin and lungs from fibrosis, a process that can ultimately end in organ failure and even death because the damaged tissue becomes scarred and can no longer function...

» Moves Toward Personalized Medicine for Scleroderma

researchers have received two five-year grants totaling $953,000 from the National Institutes of Health's (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases to study , an autoimmune disease for which there currently is no...

» Researchers Receive NIH Grant To Study Autoimmune Lung Disease

Researchers at the University of Cincinnati Interstitial Lung Disease Center have received a grant from the National Heart, Lung and Blood Institute to study ways ILD first appears in certain patient groups with autoimmune diseases and how to more...

» The Scleroderma Foundation Teams Up with Traitwise

The has teamed up with Austin, TX company, Incorporated, to launch a unique survey to poll thousands of patients and their caregivers. Data from the survey will be shared with researchers nationally and internationally in an effort to improve...

» New Hope for Patients

Pulmonary Fibrosis (PF) and (PAH) are incurable rare lung diseases and are the leading cause of mortality in patients with Systemic Sclerosis (SSc). However patients might have a reason to breathe easier since researchers from the University of...

Add comment

Do feel free to leave your comments, as they would add value and knowledge to the community. However, please refrain from making any disparaging, uninformed, or unrelated comments. Thanks :)

Security code
Refresh